Capsule Summary Slidesets

Share

Program Content

Activities

  • COMMANDS Luspatercept
    COMMANDS: Long-term Outcomes of the Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

    Expires: December 08, 2025

  • GFM COMBOLA
    GFM COMBOLA Part A: Phase I/II Study of Luspatercept + EPO in Patients With Lower-Risk, Ring Sideroblast–Negative MDS After ESA Failure
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2024

    Expires: December 09, 2025

  • IMerge Pooled Analysis
    IMerge Pooled Analysis: Effect of Previous Treatments on Imetelstat Activity in RBC Transfusion–Dependent LR-MDS Relapsed/Refractory to ESAs
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2024

    Expires: December 09, 2025

  • Early vs Late ESA for Anemia in Lower Risk MDS
    EPO-PRETAR: Phase III Trial of Early vs Late Initiation of ESA Treatment in Patients With Lower-Risk MDS and Anemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2024

    Expires: December 09, 2025

  • BOREAS
    BOREAS: Phase III Trial of Navtemadlin vs Best Available Therapy in Patients With JAK Inhibitor R/R Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

    Expires: December 10, 2025

  • DAC + ATRA for MDS EB
    Decitabine Plus ATRA for Newly Diagnosed MDS With Excessive Blasts
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2024

    Expires: December 15, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation